rovaleucel (TT10) / Tessa Therap - LARVOL DELTA

Gemcitabine, carboplatin, and Epstein Barr virus-specific autologous cytotoxic T lymphocytes for recurrent or metastatic nasopharyngeal carcinoma: VANCE, an international randomized Phase 3 trial. (PubMed, Ann Oncol) - P3 | "GC+EBV-CTL in subjects with R/M NPC demonstrated a favorable safety profile but no overall improvement in OS vs. chemotherapy. This is the largest adoptive T cell therapy trial reported in solid tumors to date."

Journal • Metastases • P3 data • Epstein-Barr Virus Infections • Head and Neck Cancer • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

Randomized phase III VANCE study: Gemcitabine and carboplatin (GC) followed by Epstein Barr virus-specific autologous cytotoxic T lymphocytes (EBV-CTL) versus the same chemotherapy as first-line treatment for advanced nasopharyngeal carcinoma (NPC) (ESMO 2022) - "Thirteen out of 133 patients treated with EBV-CTL (9.8%) experienced EBV-CTL related AEs, all grade 1 and 2, except two grade 3 events of anemia and leukopenia that occurred in one patient. Conclusions EBV-CTL as first-line treatment in patients with R/M NPC had a favorable safety profile but did not demonstrate a longer OS vs standard of care (SOC) chemotherapy."

Clinical • P3 data • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (clinicaltrials.gov) - P3 | N=330 | Completed | Sponsor: Tessa Therapeutics | Active, not recruiting ➔ Completed | Trial completion date: Jan 2023 ➔ Feb 2022 | Trial primary completion date: Jan 2023 ➔ Feb 2022

Trial completion • Trial completion date • Trial primary completion date • Epstein-Barr Virus Infections • Nasopharyngeal Carcinoma • Oncology • Solid Tumor

A Phase III Trial Evaluating Chemotherapy and Immunotherapy for Advanced Nasopharyngeal Carcinoma (NPC) Patients (clinicaltrials.gov) - P3; N=330; Active, not recruiting; Sponsor: Tessa Therapeutics; Trial primary completion date: Feb 2021 ➔ Jan 2023

Clinical • Trial primary completion date • Epstein-Barr Virus Infection • Nasopharyngeal Carcinoma • Oncology • Solid Tumor